[A24-71] Axicabtagene ciloleucel (DLBCL and HGBL, second line) – Benefit assessment according to §35a Social Code Book V
Last updated 01.10.2024
Project no.:
A24-71
Commission:
Commission awarded on 01.07.2024 by the Federal Joint Committee (G-BA).
Report type:
Dossier assessment
Status:
Commission completed
Department/Division:
Drug Assessment
Application field:
Cancer
Adults with diffuse large B-cell lymphoma or high-grade B-cell lymphoma that relapses within 12 months from completion of, or is refractory to, first-line chemoimmunotherapy, and who are candidates for high-dose therapy
Hint of minor added benefit
After completion of the assessment by IQWiG the Federal Joint Committee (G-BA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the G-BA website.
https://dx.doi.org/10.60584/A24-71
| Project no. | Title | Status |
|---|---|---|
| A23-65 | Axicabtagene ciloleucel (DLBCL and PMBCL, third line) – Benefit assessment according to §35a Social Code Book V | Commission completed |
| A23-63 | Axicabtagene ciloleucel (follicular lymphoma) – Benefit assessment according to §35a Social Code Book V | Commission completed |
| A23-66 | Axicabtagene ciloleucel (diffuse large B-cell lymphoma, second line) – Benefit assessment according to §35a Social Code Book V | Commission completed |
| G22-19 | Axicabtagene ciloleucel (diffuse large B-cell lymphoma and primary mediastinal large B-cell lymphoma) - Assessment according to §35a (para. 1, sentence 11) Social Code Book V (expiry of the decision) | Commission completed |
| G18-18 | Axicabtagene ciloleucel (B-cell lymphoma DLBCL) - Assessment according to §35a (para. 1., sentence 11) Social Code Book V | Commission completed |
| G18-19 | Axicabtagene ciloleucel (B-cell lymphoma PMBCL) - Assessment according to §35a (para. 1., sentence 11) Social Code Book V | Commission completed |